Premium
Exosomes Enter Vaccine Development: Strategies Meeting Global Challenges of Emerging Infections
Author(s) -
Jungbauer Alois
Publication year - 2018
Publication title -
biotechnology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.144
H-Index - 84
eISSN - 1860-7314
pISSN - 1860-6768
DOI - 10.1002/biot.201700749
Subject(s) - ebola virus , virology , vaccination , virus , ebolavirus , ns3 , exosome , microvesicles , biology , hepatitis c virus , microrna , biochemistry , gene
New approaches for vaccination must be developed in order to meet the grand challenges for emerging infectious diseases. Exosomes now enter vaccine development and these are strategies are meeting these global challenges, as demonstrated by Anticoli et al., in this issue of Biotechnology Journal . Using exosome vaccines has been now been demonstrated in vivo for several viruses such as Ebola Virus VP24, VP40, and NP, Influenza Virus NP, Crimean‐Congo Hemorrhagic Fever NP, West Nile Virus NS3, and Hepatitis C Virus NS3. Now this technology must be tested in clinics.